Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Zura Bio Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2024
FY2025
Research and development
23.7
44
24.4
42.1
General and administrative
3.47
18.6
30.8
33.2
Operating expenses
27.2
62.6
55.2
75.2
Operating income
-27.2
-62.6
-55.2
-75.2
Interest income
0.01
2.19
8
6.34
Other non-operating income
6.22
2.08
2.79
6.6
Pre-tax income
-27.3
-60.6
-52.4
-68.7
Income tax
0
0
Net income
-25.7
-60.4
-52.4
-68.7
EBITDA
-55.2
-75.2
EPS, basic
-141.97
-2.09
-0.60
-1.06
EPS, diluted
-141.97
-2.09
-0.60
-1.06
Shares, basic (weighted)
0.23
33.1
75.1
94.2
Shares, diluted (weighted)
0.23
33.1
75.1
94.2
Balance sheet
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.01
99.8
176
109
Other current assets
0.02
1.04
2.25
2.9
Total current assets
1.78
101
179
112
Property, plant and equipment
0.09
0.13
Other non-current assets
0.7
1.51
Total assets
5.26
101
180
114
Accounts payable
2.01
2.75
0.73
1.28
Accrued liabilities
1.11
Total current liabilities
14.8
20.3
19.5
12.4
Total liabilities
14.8
21.3
19.5
12.4
Paid-in capital
163
303
326
Retained earnings
-32.1
-103
-156
-225
Shareholders' equity
-32.1
59.3
147
102
Minority interests
0
1.54
1.54
Total equity
-32.1
60.9
148
102
Total liabilities and equity
5.26
101
180
114
Shares outstanding
0.28
43.6
65.3
73.7
Cash flow statement
FY2022
FY2023
FY2024
FY2025
Net income
-27.3
-60.6
-52.4
-68.7
Depreciation and amortization
0.01
0.05
Stock-based compensation
0.33
7.47
16.8
12.3
Change in payables
0.21
5.94
4.21
-2.16
Cash from operations
-1.2
-15.1
-28.1
-64.8
Capital expenditures
-0.08
-0.11
Cash from investing
-12
-8
-5.08
-0.11
Stock issued
56.7
0.11
Cash from financing
14.8
121
110
-2.16
Net change in cash
-0.72
98.2
76.7
-67.1
Free cash flow
-28.2
-64.9
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.04 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-40.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-30.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-36.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
178.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
25.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
644.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.9x
Current assets / current liabilities.
Quick ratio
12.6x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
12.6x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
7.6%
Total liabilities / total assets.
Working capital
$194.2M
Current assets - current liabilities.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.68
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
FCF yield
-16.8%
Free cash flow / market cap.
Earnings yield
-22.1%
Net income / market cap (the inverse of P/E).
Was Zura Bio Ltd profitable in fiscal 2025?
No. It reported a net loss of $68.7M.
How much free cash flow did Zura Bio Ltd generate in fiscal 2025?
Cash from operations of $64.8M minus capital expenditures of $113.0K left free cash flow of -$64.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.